Guggenheim Keeps Their Buy Rating on Verastem (VSTM)
TipRanks (Tue, 16-Dec 7:35 AM ET)
Verastem Oncology announces management changes
Seeking Alpha News (Mon, 15-Dec 4:34 PM ET)
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Business Wire (Mon, 15-Dec 4:01 PM ET)
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Business Wire (Tue, 25-Nov 7:30 AM ET)
Verastem Oncology Prices $90 Million Offering to Accelerate Cancer Therapy Pipeline
Market Chameleon (Fri, 14-Nov 3:18 AM ET)
Business Wire (Fri, 14-Nov 12:41 AM ET)
Verastem Oncology Announces Proposed Public Offering of Common Stock
Business Wire (Thu, 13-Nov 4:07 PM ET)
Verastem Oncology to Present at Upcoming Investor Conferences
Business Wire (Wed, 5-Nov 7:30 AM ET)
Verastem Oncology's Q3 Performance Underscores Momentum in RAS/MAPK Drug Development
Market Chameleon (Tue, 4-Nov 4:16 AM ET)
Business Wire (Tue, 4-Nov 7:30 AM ET)
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Verastem trades on the NASDAQ stock market under the symbol VSTM.
As of December 17, 2025, VSTM stock price declined to $7.99 with 2,490,420 million shares trading.
VSTM has a beta of 0.52, meaning it tends to be less sensitive to market movements. VSTM has a correlation of 0.01 to the broad based SPY ETF.
VSTM has a market cap of $601.81 million. This is considered a Small Cap stock.
Last quarter Verastem reported $11 million in Revenue and -$.54 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.03.
In the last 3 years, VSTM traded as high as $15.18 and as low as $2.10.
The top ETF exchange traded funds that VSTM belongs to (by Net Assets): VTI, XBI, IWM, VXF, FESM.
VSTM has outperformed the market in the last year with a return of +70.7%, while the SPY ETF gained +12.1%. However, in the most recent history, VSTM shares have underperformed the stock market with its stock returning -12.5% in the last 3 month period and -18.3% for the last 2 week period, while SPY has returned +2.2% and -1.3%, respectively.
VSTM support price is $8.29 and resistance is $9.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VSTM shares will trade within this expected range on the day.